Reported Sunday, Cullinan Therapeutics Reports Velinotamig Achieved Clinically Meaningful Disease Activity Improvement In 8 Of 9 Evaluable Refractory Lupus Patients, With Four Complete Renal Responses, In Data Presented At ACR Convergence 2026

Benzinga · 6d ago
  • Clinically meaningful improvement in disease activity among 8 of 9 evaluable patients, including rapid and marked reductions in proteinuria with complete renal responses 
  • Deep and sustained reduction in pathogenic autoantibodies and IgG reduction underscore potential in plasma-cell driven diseases
  • Favorable safety profile in patients with refractory SLE